Skip to main content

Ivelin Georgiev Archives

Children’s antibodies highly potent against COVID-19: study

Nov. 6, 2023—Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.

Read more


NIH grant launches C. diff vaccine research initiative

Mar. 30, 2023—Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.

Read more


Discovery of “cross-reactive” antibodies could aid treatment of viral co-infections

Feb. 2, 2023—  by Bill Snyder More than a million people in the United States are living with HIV, the virus that causes AIDS. One-fifth of them have been co-infected by the hepatitis C virus (HCV), which attacks the liver. Curative drugs for HCV are available, but many people don’t know they’ve been infected. And if they...

Read more


Antibody “fingerprinting” method potential advance to slow spread of dengue

Jan. 12, 2023—Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

Read more


Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

Jul. 20, 2022—In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

Read more


Grant set to support Georgiev’s research to identify new antibodies

Mar. 24, 2022—Vanderbilt's Ivelin Georgiev, PhD, has received a three-year, $750,000 award from The G. Harold and Leila Y. Mathers Foundation of Rye Brook, New York, to support research aimed at rapidly identifying potent, disease-fighting antibodies.

Read more


Technique hastens COVID-19 antibody discovery

Mar. 10, 2022—Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.

Read more


“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Read more


Grant helps expand VI4’s Artist-in-Residence program

Oct. 29, 2020—An innovative Vanderbilt program that brings together scientists and artists with the shared goal of scientific communication is set to expand with support from a three-year grant from the Burroughs Wellcome Fund.

Read more


Two VUMC researchers named 2020 Chancellor Faculty Fellows

Jun. 23, 2020—Two Vanderbilt University Medical Center researchers -- Jennifer (Piper) Below, PhD, associate professor of Medicine, and Ivelin Georgiev, PhD, associate professor of Pathology, Microbiology and Immunology -- have been selected for the 2020 cohort of Chancellor Faculty Fellows at Vanderbilt University.

Read more


New tool may speed antibody, vaccine research

Dec. 12, 2019—  by Allison Whitten The antibody discovery and vaccine development research fields may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues. Currently, due to technological constraints, it can take up to a year to...

Read more


A “public” target for HIV

Jun. 8, 2018—Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more